Scientists design protein that prods cancer-fighting T-cells

Scientists at UW Medicine’s Institute for Protein Design have created a new protein that mimics the action of a key immune regulatory protein, interleukin 2 (IL-2). IL-2 is a potent anticancer drug and an effective treatment for autoimmune disease, but its toxic side effects have limited its clinical usefulness.

In a paper in the Jan. 10 issue of the journal Nature, the researchers report using computer programs to design a protein that they have shown in animal models to have the same ability to stimulate cancer-fighting T-cells as the naturally occurring IL-2, but without triggering harmful side effects.

The achievement opens new approaches to the design of protein-based therapeutics for the treatment of cancer, autoimmune diseases and other disorders, the researchers said.

The new protein has been dubbed Neo-2/15 because, in addition to mimicking the effect of IL-2, the protein can also mimic the effect of another interleukin, IL-15, which is being studied as another possible anticancer immunotherapy.

“People have tried for 30 years to alter IL-2 to make it safer and more effective, but because naturally occurring proteins tend not to be very stable, this has proved to be very hard to do,” said a lead author of the paper, Daniel-Adriano Silva, an IPD biochemist. “Neo-2/15 is very small and very stable. Because we designed it from scratch, we understand all its parts, and we can continue to improve it making it even more stable and active.”

“Neo-2/15 has therapeutic properties that are at least as good as or better than naturally occurring IL-2, but it was computationally designed to be much less toxic,” said another lead author, Umut Ulge, an internal medicine physician and IPD biochemist.

IL-2 has been used as a last-ditch treatment for cancer patients with no other therapeutic options. For some patients with advanced melanoma or renal cell carcinoma, IL-2 can achieve cure rates as high as 7 percent. Its use, however, is limited because it can be given safely only to the healthiest patients and only in intensive-care units at specialized medical centers.

IL-2 acts on two kinds of immune cells by binding to receptors on the cells’ surface. The effect IL-2 has on a cell’s behavior depends in large part on the number and nature of these receptor interactions. Natural IL-2 can activate cells with beta and gamma receptors responsible for anti-tumor activity, which is exactly what the patient would want. However, natural IL-2 preferentially binds to another kind of immune cell which has alpha receptors in addition to beta and gamma receptors. These cells cause disastrous side effects like severe toxicity and immunosuppression. To date, all approved IL-2 therapies unfortunately cause preferential activation of these off-target cells.

The new protein, however, does not preferentially bind to the harmful cells. This new molecule enables activation of on-target tumor-fighting cells without preferentially activating the off-target cells responsible for toxicity and immunosuppression.

To design a cancer-fighting protein that would not cause these side effects, the researchers used a computer program developed in the Baker lab called Rosetta. Using Rosetta, the researchers designed their protein to have surfaces that would bind to and activate IL-2 receptor beta and gamma, but not the IL-2 receptor alpha, which is part of the harmful cells.

First, researchers designed compact proteins to serve as scaffolds for holding the two binding sites in proper position. Then they optimized the amino acid sequence of the best scaffolds. This effort resulted in a final compact protein that is completely different from natural IL-2. In laboratory and animal models it avidly bound to IL-2 receptor beta and gamma, activated cancer-fighting immune cells, and slowed tumor growth. Because the designed protein had no binding site for the alpha receptor, effective doses of Neo-2/15 did not cause toxic side effects.

The finding shows that designing proteins from scratch can lead to bio-superior molecules with enhanced therapeutic properties and lesser side effects for virtually any biological molecule whose structure is known or can be predicted, suggested lead researcher and institute director David Baker. He is a UW professor of biochemistry and a Howard Hughes Medical Institute investigator.

Other lead authors include Shawn Yu of the IPD and Jamie Spangler of the Department of Chemical and Biomolecular Engineering at Johns Hopkins University.

CoMotion, the collaborative innovation hub dedicated to expanding the economic and societal impact of the UW community, has worked with the researchers to file patent applications on the newly designed proteins and enabling technology. A startup company, Neoleukin Therapeutics, Inc. has rights to the intellectual property. Jonathan Drachman, CEO of Neoleukin Therapeutics, will be leading the efforts of the company to drive the innovation forward towards clinical development and commercialization. Several of the scientific inventors from the Institute of Protein Design, including Silva, Ulge, and Carl Walkey, are co-founders and will be joining the new company.

Watch this discussion.Stop watching this discussion.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language.PLEASE TURN OFF YOUR CAPS LOCK.Don't Threaten. Threats of harming another
person will not be tolerated.Be Truthful. Don't knowingly lie about anyone
or anything.Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person.Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts.Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.